Server: Microsoft-IIS/3.0 Date: Thu, 18 Dec 1997 17:56:45 GMT Content-Type: text/html Accept-Ranges: bytes Last-Modified: Wed, 12 Nov 1997 19:10:06 GMT Content-Length: 3843
Neurobiological Technologies, Inc. Completes Enrollment in Phase II Trial for Neuropathic Pain
Neurobiological Technologies, Inc. Announces First Quarter Results
Neurobiological Technologies, Inc. Announces Fiscal Year End Results
Neurobiological Technologies, Inc. Executive Vice President Resigns
Neurobiological Technologies, Inc. Applies for Orphan Drug Status of Xerecept™
Neurobiological Technologies, Inc. Files IND for Xerecept™
Neurobiological Technologies Reports Third Quarter Results
Neurobiological Technologies, Inc. Starts Phase II Memantine Trial
Neurobiological Technologies, Inc. Announces Resignation of Director and Stock Purchases by Insiders
Paul Freiman and Abraham Sofaer Join Board of Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc. Announces Second Quarter Results
Neurobiological Technologies, Inc. Announces Results of Rheumatoid Arthritis Trial
Neurobiological Technologies, Inc. Starts Phase II Memantine Trial with NIH AIDS Unit
NTII Initiates Neuroprotection Research Program with Children's Hospital in Boston
Profile | Pipeline | Financial | Stock Info | Neuroprotection | Press Releases | Glossary | Contacts